Pharming Group N.V. ( (PHGUF) ) has released its Q4 earnings. Here is a breakdown of the information Pharming Group N.V. presented to its investors.
Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases, with a notable presence in the protein replacement therapy sector.
In its latest earnings report, Pharming Group announced a 21% increase in total revenues for 2024, reaching $297.2 million, surpassing their guidance. This growth was primarily driven by record revenues from RUCONEST® and significant growth in Joenja® sales.
Key financial highlights include a 14% increase in fourth-quarter revenues to $92.7 million and a notable rise in operating profit to $6.7 million from $1.1 million in the previous year. The company also completed the acquisition of Abliva AB, enhancing its clinical pipeline with KL1333 for mitochondrial diseases. Pharming’s strategic focus on expanding its market reach for leniolisib and advancing clinical trials for primary immunodeficiencies is evident.
Looking ahead, Pharming Group anticipates revenue growth between $315 million and $335 million for 2025, with continued investments in expanding its product portfolio and advancing its R&D pipeline. The company remains committed to serving the rare disease community and creating long-term value for stakeholders.